JP2001513487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001513487A5 JP2001513487A5 JP2000506830A JP2000506830A JP2001513487A5 JP 2001513487 A5 JP2001513487 A5 JP 2001513487A5 JP 2000506830 A JP2000506830 A JP 2000506830A JP 2000506830 A JP2000506830 A JP 2000506830A JP 2001513487 A5 JP2001513487 A5 JP 2001513487A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- drug
- use according
- arachidonic acid
- zinc cation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 18
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 16
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 15
- 229940006486 zinc cation Drugs 0.000 description 15
- 229940114079 arachidonic acid Drugs 0.000 description 12
- 235000021342 arachidonic acid Nutrition 0.000 description 12
- 229960002885 histidine Drugs 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- -1 zinc cations Chemical class 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/909,240 US5834032A (en) | 1997-08-11 | 1997-08-11 | Compositions and methods for treating diabetes |
| US08/909,240 | 1997-08-11 | ||
| PCT/US1998/016321 WO1999007224A1 (en) | 1997-08-11 | 1998-08-06 | Compositions and methods for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001513487A JP2001513487A (ja) | 2001-09-04 |
| JP2001513487A5 true JP2001513487A5 (enExample) | 2006-01-05 |
Family
ID=25426873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000506830A Pending JP2001513487A (ja) | 1997-08-11 | 1998-08-06 | 糖尿病治療用組成物及び治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5834032A (enExample) |
| JP (1) | JP2001513487A (enExample) |
| KR (1) | KR100533618B1 (enExample) |
| CN (1) | CN1216635C (enExample) |
| AU (1) | AU8693098A (enExample) |
| WO (1) | WO1999007224A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750336A (en) * | 1994-02-10 | 1998-05-12 | The Salk Institute For Biological Studies | Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes |
| WO2000018392A1 (en) * | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
| JP2001220348A (ja) * | 1999-11-30 | 2001-08-14 | Japan Science & Technology Corp | 亜鉛（ｉｉ）有機錯体からなる血糖降下剤 |
| JP5048201B2 (ja) | 2000-08-04 | 2012-10-17 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物 |
| JP4161031B2 (ja) * | 2000-10-31 | 2008-10-08 | 独立行政法人産業技術総合研究所 | 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤 |
| JP2003040784A (ja) * | 2001-01-31 | 2003-02-13 | Japan Science & Technology Corp | 血糖降下剤 |
| DK1571970T3 (da) * | 2002-10-02 | 2011-11-28 | Dmi Biosciences Inc | Diagnose og monitorering af sygdomme |
| US6989025B2 (en) * | 2002-10-04 | 2006-01-24 | Boston Scientific Scimed, Inc. | Extruded tubing with discontinuous striping |
| US7524517B2 (en) * | 2003-01-17 | 2009-04-28 | Uab Research Foundation | Methods and compositions for P2X receptor calcium entry channels and other calcium entry mechanisms |
| DE602004011275T2 (de) * | 2003-01-31 | 2009-01-15 | Moon K. Northridge Song | Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit |
| CN102210852B (zh) | 2003-05-15 | 2016-10-19 | 安皮奥制药股份有限公司 | T-细胞介导的疾病的治疗 |
| JP2008538547A (ja) * | 2005-03-09 | 2008-10-30 | ロジャー・ウィリアムズ・ホスピタル | 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法 |
| US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
| KR101530050B1 (ko) * | 2007-03-02 | 2015-06-22 | 주식회사 노브메타파마 | 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법 |
| JP5856843B2 (ja) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
| EP2613786A4 (en) | 2010-09-07 | 2013-10-23 | Dmi Acquisition Corp | TREATMENT OF DISEASES |
| JP2014530063A (ja) | 2011-10-10 | 2014-11-17 | アンピオ ファーマシューティカルズ，インコーポレイテッド | 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法 |
| PH12014500685B1 (en) | 2011-10-10 | 2018-10-03 | Ampio Pharmaceuticals Inc | Treatment of degenerative joint disease |
| HK1198812A1 (en) | 2011-10-28 | 2015-06-12 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
| CA2906864A1 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| CN106456633A (zh) * | 2014-06-20 | 2017-02-22 | 三得利控股株式会社 | 糖代谢改善剂 |
| EP4066836A1 (en) | 2014-08-18 | 2022-10-05 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES |
| CN105748564A (zh) * | 2015-12-21 | 2016-07-13 | 天津中津药业股份有限公司 | 一种治疗糖尿病的药物组合物 |
| WO2019078663A2 (ko) | 2017-10-20 | 2019-04-25 | 주식회사 노브메타파마 | 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 |
| WO2019098811A2 (ko) * | 2017-11-20 | 2019-05-23 | 주식회사 노브메타파마 | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
| US20210177932A1 (en) * | 2017-12-11 | 2021-06-17 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for prevention and treatment of immune deficiency and inflammation |
| KR20190074746A (ko) * | 2017-12-20 | 2019-06-28 | 주식회사 노브메타파마 | 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제 |
| US20200345728A1 (en) * | 2019-04-30 | 2020-11-05 | Novmetapharma Co., Ltd. | Compositions and methods for treatment of atherosclerosis |
| KR102115353B1 (ko) * | 2019-05-17 | 2020-05-26 | 주식회사 노브메타파마 | Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
| ES2972490T3 (es) * | 2019-12-20 | 2024-06-13 | Vector Vitale Ip Llc | Composición y método para el tratamiento de la diabetes de tipo I |
| KR20230025709A (ko) | 2020-06-17 | 2023-02-22 | 주식회사 노브메타파마 | 바이러스 감염을 치료하기 위한 조성물 및 방법 |
| BR112023003263A2 (pt) | 2020-09-04 | 2023-03-21 | Nestle Sa | Composições e métodos para fornecer benefícios de saúde a um animal |
| KR20240032221A (ko) * | 2022-08-31 | 2024-03-12 | 주식회사 노브메타파마 | 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 호흡기 질환의 예방, 개선 또는 치료용 조성물 |
| KR20250066976A (ko) | 2023-11-07 | 2025-05-14 | 주식회사 노브메타파마 | 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 당뇨병성 신증의 예방, 개선 또는 치료용 조성물 |
| KR20250076353A (ko) | 2023-11-21 | 2025-05-29 | 주식회사 노브메타파마 | 글루콘산 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물 |
-
1997
- 1997-08-11 US US08/909,240 patent/US5834032A/en not_active Expired - Lifetime
-
1998
- 1998-08-06 AU AU86930/98A patent/AU8693098A/en not_active Abandoned
- 1998-08-06 JP JP2000506830A patent/JP2001513487A/ja active Pending
- 1998-08-06 CN CN988079313A patent/CN1216635C/zh not_active Expired - Fee Related
- 1998-08-06 KR KR10-2000-7001386A patent/KR100533618B1/ko not_active Expired - Lifetime
- 1998-08-06 WO PCT/US1998/016321 patent/WO1999007224A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4850880B2 (ja) | 疼痛の処置のためのエピナスチンの使用 | |
| TW518222B (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| JP2005537268A5 (enExample) | ||
| Pasquier et al. | “Hemicrania continua”: The first bilateral case? | |
| JPH07215859A (ja) | 月経時の症状の治療法およびそれに用いる組成物 | |
| EP0920865B1 (en) | Pharmaceutical compositions containing Norastemizole | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JPS59112948A (ja) | コレステロ−ルレベル低下剤 | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| JP2002544227A5 (enExample) | ||
| Veterans Administration Cooperative Study Group on Antihypertensive Agents et al. | Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension | |
| JPS63270626A (ja) | 抗潰瘍剤 | |
| JPH037218A (ja) | 薬剤組成物 | |
| JPS5942649B2 (ja) | 重症筋無力症治療剤 | |
| KR0178762B1 (ko) | 특정 인돌 유도체의 신규 의약적 용도 및 그를 함유하는 제약 조성물 | |
| JPS58109420A (ja) | 月経痛を減少させるための方法及び組成物 | |
| JPH05246845A (ja) | イブプロフェン含有解熱鎮痛剤 | |
| SHEIDLER et al. | Double‐blind multiple‐dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine | |
| JP6087988B2 (ja) | 鼻汁分泌抑制用組成物 | |
| Curson et al. | Mianserin and agranulocytosis. | |
| Bittar | Usefulness of nifedipine for myocardial ischemia and the nifedipine gastrointestinal therapeutic system | |
| US5292497A (en) | Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate | |
| JPH0149124B2 (enExample) | ||
| RU2003100081A (ru) | Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии |